-+ 0.00%
-+ 0.00%
-+ 0.00%

Voyager wins FDA IND clearance for Alzheimer’s gene therapy VY1706

PUBT·07/13/2026 12:11:55
Listen to the news
Voyager wins FDA IND clearance for Alzheimer’s gene therapy VY1706
  • Voyager Therapeutics received FDA IND clearance for VY1706, enabling a clinical trial in adults with early Alzheimer’s disease.
  • Dosing is expected to begin in H2 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Therapeutics Inc. published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein.